Rani Therapeutics posted a $8.8 million Q3 net loss while securing FDA Emerging Technology Program acceptance and reporting $45.3 million in liquidity to fund operations through 2027.
Third-quarter net loss widened to $8.8 million from $7.9 million a year earlier, while cash, equivalents and marketable securities stood at $45.3 million as of September 30, 2026, said to fund operations at least through end-2027. Offsetting the loss, October acceptance into the FDA's Emerging Technology Program is a tangible regulatory milestone and contract revenue of $1.7 million appeared versus none last year. Positive regulatory progress and mixed financials largely cancel out, leaving the RT-114 data expected by year-end as the real swing factor.
Rani Therapeutics Holdings reported a third-quarter net loss of $8.8 million, widening from $7.9 million in the same period last year. Despite the loss, the company secured acceptance into the FDA's Emerging Technology Program in October to support its RaniPill platform. Management maintains a cash position of $45.3 million, which is expected to fund operations through the end of 2027.
$45.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, which management says funds operations at least through the end of 2027.
It allows Rani early engagement with the FDA on technical, manufacturing and regulatory questions about the RaniPill platform while the company automates its manufacturing process.